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Key points 
 Jaw osteonecrosis (ONJ) develops in a small subgroup of individuals exposed to 
bisphosphonate medications.  
 Although a number of associated clinical risk factors have been identified, it 
remains difficult to predict which individuals will eventually develop ONJ.  
 Pharmacogenetics has the potential to identify genetic variants associated with an 
increased risk (susceptibility) of developing ONJ. 
 A number of genome wide association and candidate gene studies have been 
performed during the last few years; however they are limited by small cohort size 
and lack of robust genomic statistical significance. 
 The study of genetic susceptibility to ONJ requires international multicentre 
collaborative networks and larger and better phenotyped cohorts. 
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Synopsis/Abstract 
Osteonecrosis of the jaws (ONJ) is a potentially severe disorder that develops in a 
subgroup of individuals who use or have used bisphosphonate medications (BP). A 
number of clinical risk factors have been associated with the risk of ONJ 
development, however evidence is limited and in most instances ONJ remains an 
unpredictable ADR. Inter-individual genetic variability can contribute to explaining 
ONJ development in a subset of BP users and the discovery of relevant associated 
gene variants could lead to the identification of individuals at higher risk. A number of 
small pharmacogenetic studies have been performed during the last few years but 
no genetic variant has been found to be robustly associated with the susceptibility to 
ONJ. 
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Introduction 
Bisphosphonates (BPs) are anti-resorptive agents commonly used in treatment of 
osteoporosis, multiple myeloma and bone metastases from solid cancers [1]. BPs 
are internalised into osteoclasts via endocytosis and result in the inhibition of 
osteoclast activity through different mechanisms [2, 3]. Nitrogen-containing BPs, 
including alendronate, ibandronate, risedronate, pamidronate and zoledronate, 
inhibit farnesyl pyrophosphate synthase, a key enzyme of the mevalonate pathway. 
This (i) prevents prenylation of guanosine triphosphatase (GTPase), which is 
essential for osteoclast function and survival, and (ii) causes accumulation of 
isopentenyl diphosphate, which in turn can induce osteoclast apoptosis [4]. Non-
nitrogen-containing BPs, including clodronate and etidronate, are incorporated into 
adenosine triphosphate (ATP) analogue, which can also induce osteoclast apoptosis 
[5]. 
BPs are associated with a potentially severe adverse drug reaction (ADR): 
osteonecrosis of the jaw (ONJ), which was initially reported in 2003 [6]. Since then, 
thousands of ONJ cases have been reported worldwide [7]. ONJ is characterised by 
the development of jawbone necrosis and is traditionally presented with areas of 
exposed necrotic jawbone through mucosal or facial skin fenestrations ranging from 
a few millimetres to several centimetres [8–10]. More recent studies have reported 
that in approximately 25% of cases ONJ can also present without soft tissue 
fenestration (non-exposed variant), with affected patients showing otherwise 
unexplained painful symptoms, intra-oral or extra-oral fistulae, tooth mobility or tooth 
loss, sinusitis or mandibular facture [1, 11–13]. Both the exposed and non-exposed 
variants of ONJ can present with extensive necrosis, secondary infection and severe 
pain [14], therefore causing a significant reduction in the quality of life [15]. Figures 
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on ONJ prevalence and incidence vary widely and remain controversial. Available 
data suggests that ONJ develops in a subgroup of individuals who use or have used 
BPs: approximately 7% among those using intravenous BPs for cancer management 
and 0.12% of those who take oral BPs due to osteoporosis [16]. Little robust 
information is available regarding ONJ aetiopathogenesis; similarly, it is unclear why 
ONJ develops only in a subset of patients [17-18]. A number of clinical risk factors 
have been associated with ONJ development, including underlying malignant 
disease, use of intravenous high-potency BPs, high dose or long-term BP therapy, 
use of concomitant medications, dental infections and surgical procedures to the 
jawbones [19]. Nevertheless, relevant literature lacks robustness and consistency, 
and in most instances ONJ remains an unpredictable ADR.   
Inter-individual genetic variants are known to potentially determine disparate 
response to medications, including toxicity. It was estimated that genetic variability 
could contribute to ADR development in more than half of the medications examined 
in a systematic review [20]. Inter-individual genetic variability can therefore contribute 
to explaining ONJ development in a subset of individuals using BPs. In the past few 
years, a number of small studies investigated the potential association of ONJ 
development with genetic factors [21–31]. The aim of the present study is to provide 
a critical and comprehensive review on available evidence regarding 
pharmacogenetics of ONJ.  
 
Pharmacogenetics and adverse drug reactions (ADRs) 
By definition, pharmacogenetics is the study of how genetic differences influence the 
variability in patients' responses to drugs, including toxicity [32]. Examples of genetic 
factors contributing to individuals’ susceptibility to ADR include HLA-A*31:01 for 
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carbamazepine (CMZ)-induced skin reactions in Europeans [33], HLA-B*15:02 for 
CMZ-induced Stevens-Johnson syndrome in Asians [34], SLCO1B1 for statin-
induced myopathy [35], and HLA-B*57:01 for abacavir-induced hypersensitivity 
reactions [36-37], as well as for flucloxacillin-induced liver injury [38]. In the majority 
of cases, the genetic risk variants are drug-specific (one or a few medications) and 
population (ethnicity)-specific [33, 34, 39]. Among the drug-induced liver injuries 
(DILI), HLA-B*57:01 is only known to be associated with flucloxacillin-induced 
reactions, while HLA-DRB1*15:01 is known to be associated with both amoxicillin-
clavulanate [39] and lumiracoxib [40]. Examples of successful and cost-effective 
translation of pharmacogenetic data into clinical practice include HLA-B*57:01 
screening prior to initiating treatment with abacavir and HLA-B*15:02 screening prior 
to CMZ therapy in Asians, both recommended by the Food and Drug Administration 
(FDA) [41-42]. With such robust and growing evidence, pharmacogenetics is 
becoming a realistic mean to tailor and personalise safe and effective therapy for 
single individuals [43]. Pharmacogenetic studies comprise genome-wide association 
studies (GWAS) and candidate gene studies [44]. A total of two GWAS and nine 
candidate gene studies have been performed in relation to ONJ. 
 
GWAS on ONJ 
GWAS is a comprehensive research approach that is useful for investigating both 
complex disease and drug response including ADR. Typically, a GWAS screens 
millions of single nucleotide polymorphisms (SNPs) across the entire genome, in 
which a SNP refers to a single-base difference in DNA sequence present in at least 
1% of the general population [45]. The large set of SNPs, which form part of a 
standard GWAS genotyping chip, have been chosen based on their property of 
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being proxies to others within the same genomic region; this is known as linkage 
disequilibrium or LD [46]. A successful GWAS relies on a reasonably complete 
coverage of genetic variants, which include SNPs that are actually typed with a chip, 
as well as SNPs that have not been typed but can be predicted through LD. In other 
words, a causal variant can be a typed SNP, or an untyped one with a typed proxy 
SNP. In the latter case, “fine-mapping” studies should follow so as to search for the 
untyped causal variant in the same genomic region. GWAS usually have case-
control design and a SNP is identified as a risk factor if the frequency of its minor 
allele in the cases is significantly different than the controls. Because GWAS test 
millions of SNPs, it is possible that some variants are identified as having high 
frequency and very small p-values simply by chance; in order to avoid these false 
positives, a stringent statistical correction for multiple comparisons is commonly 
required, which is known as Bonferroni correction. Instead of the usual p<0.05, the 
significance level for GWAS is calculated as 0.05 divided by roughly 1 million SNPs, 
i.e. p<5E-08 [45].  
To date, two GWAS have been conducted on ONJ and relevant results are 
summarised in Table 1. The first GWAS, also the first pharmacogenetic study on 
ONJ, was published in 2008 by a Spanish team [21]. They studied 87 pamidronate-
treated multiple myeloma patients, who were of Spanish descent, of whom 22 had 
developed ONJ. These cases were compared with 65 drug-exposed controls who 
had not developed ONJ after a median follow-up of 64 months. 500,568 SNPs were 
screened and rs1934951 in CYP2C8 was found to be most significant, although it did 
not reach genome-wide threshold of significance (OR=12.75; 95% CI, 3.7 to 43.5; 
p=1.07E-06). . This study suggest that individuals with this SNP had nearly 13 times 
greater odds of developing ONJ than those without it. Though not directly affecting 
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BPs’ metabolism, CYP2C8 is known to be involved in osteoclast inhibition, 
osteoblast differentiation, and regulation of vascular tone, which may contribute to 
ONJ development [47].  
The second GWAS was published in 2012 and compared 30 zoledronate-treated 
breast cancer patients who had developed ONJ with 17 drug-exposed controls and 
1,726 population controls [28]. The participants were of European descent. 
Compared to the previous GWAS, 731,442 SNPs were screened. Standard 
imputation was performed to enrich the genotype dataset, and an imputed SNP, 
rs17024608 in RBMS3, was found to be associated with ONJ, with borderline 
genome-wide significance (OR=5.8; 95% CI, 3.0 to 11.0; p=7.47E-08). The 
rs17024608 carriers had approximately 6 times higher odds of developing ONJ than 
the non-carriers. RBMS3 is a gene involved in bone turnover and has been found to 
be associated with decreased bone mass and osteoporotic fracture [28]. Of note, 
CYP2C8 variants were not confirmed as risk factors for ONJ in this cohort of breast 
cancer patients.  
In summary, only two GWAS have been published so far and they suggest that 
variants in genes CYP2C8 and RBMS3, which are both related to bone turnover, 
may be associated with ONJ development in multiple myeloma patients of Spanish 
descent and in breast cancer patients of European descent respectively. There are 
significant differences between these studies as regards to cohort size, case-control 
ratio, participants’ ethnicity, underlying diseases and BPs type, which hinder 
meaningful comparison and data pooling. Also, both had relatively small number of 
cases, which limit their power to detect variants with high relative risk and represent 
the most likely cause for their failure to identify genome-wide significant variants. 
Another important aspect of GWAS is the need to replicate results in an independent 
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population with similar phenotype, which is considered the gold standard approach 
so to minimise the risk that potential technical or methodological biases could 
determine a spurious association signal [48-49]. A small number of candidate gene 
studies and one meta-analysis aimed at replicating association with rs1934951 in 
CYP2C8 (detailed below), whereas there remains no attempted replication of 
rs17024608 in RBMS3. 
 
Candidate gene studies on ONJ 
Similar to GWAS, candidate gene studies often have a case-control design [50]. In 
general they focus on potentially biologically relevant genes; for ADR, most of the 
established and high risk genetic risk factors are relevant to drug metabolism or 
transporters genes [39]. In contrast to GWAS, candidate gene studies screen much 
fewer variants and do not represent a hypothesis-free approach [51]. They are also 
prone to methodological weaknesses as they typically have small cohort size, no 
Bonferroni correction for the p-value, and often do not correct for the ethnicity of the 
cohort. Therefore, it has been suggested that candidate gene design is more suitable 
for replication studies [52]. A total of nine candidate gene studies on ONJ were 
published between 2010 and 2013 [22–27, 29–31], including both replication and 
discovery gene studies.  
Replication candidate gene studies  
Four candidate gene studies attempted to replicate the results of the Spanish GWAS 
[21] through investigating the possible association between rs1934951 in CYP2C8 
and ONJ in their respective independent cohorts [22-23, 27, 30] (Table 2).  All 
studies failed to confirm that this variant is significantly associated with the trait 
(p>0.05). Paradoxically, Katz et al. [23] and English et al. [22] reported a protective 
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OR for this variant. These apparently contradicting results are likely to be related to 
the design of the replication studies, which failed to investigate populations 
phenotypically and ethnically similar to that of the original discovery study. In 
contrast to the first GWAS, none of the four studies included individuals of Spanish 
descent, although their cohorts consisted mainly of White or Caucasian participants; 
African Americans were also inappropriately included [22-23]. Also, all four cohorts 
were predominantly exposed to zoledronate instead of pamidronate. Further, only 
two replication studies focused on multiple myeloma patients [23, 27] whereas one 
recruited individuals with metastatic prostate cancer [22], and one included 
individuals with osteoporosis and a wide range of malignant disorders [30]. A recent 
meta-analysis by Zhong et al. attempted data pooling from the four candidate gene 
replication studies and the discovery Spanish GWAS [53]. They confirmed that 
rs1934951 in CYP2C8 is not associated with ONJ across the whole merged 
population (OR=2.05; 95% CI, 0.67 to 6.29; p=0.2), but it might be associated with 
ONJ development in multiple myeloma patients with a dominant effect (OR=5.77; 
95% CI, 1.21 to 27.63; p=0.03, combined effect from only two studies [21, 27]). 
Better-designed studies are required for appropriate replication of rs1934951. There 
remains no published attempted replication of rs17024608. 
Discovery candidate gene studies  
Six discovery candidate gene studies investigated variants in genes other than 
CYP2C8 and are summarised in Table 3 [23–26, 29, 31]. These studies analysed 
the separate and combined effects of variants located in several genes, which had 
been chosen as they may relate to BPs metabolism and/or ONJ pathogenesis, e.g. 
bone turnover. Most of them screened only a small number of variants, and had 
relatively small cohorts, and are therefore susceptible to methodological limitations 
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such as inadequate power. Of note, none of the SNPs tested reached the genome-
wide significance level, i.e. p<5E-08.  
The largest discovery candidate gene study in the literature compared 94 ONJ cases 
with 110 ethnicity matched BPs-exposed controls [31]. The cohort included 
individuals with malignant disorders, including multiple myeloma, breast and prostate 
cancer, who had been exposed mainly to zoledronate or pamidronate. The study 
hypothesis was that ONJ susceptibility might be linked to the major histocompatibility 
complex (MHC) class II system, which encodes HLA class II alleles. As mentioned 
above, HLA alleles are major genetic risk factors for ADRs and are also associated 
with the adaptive immune system and infection, which in the case of ONJ may be 
related to the antigen-presenting function of osteoclasts and increased infection 
and/or inflammation [17]. According to the significance threshold set by the study, 
two independent HLA haplotypes, DRB1*01/DRB1*15 and 
DQB1*05:01/DQB1*06:02, were found to be significantly associated with ONJ 
development (uncorrected p≤0.05), with OR>2. Moreover, the association appeared 
to be stronger when more than one haplotype were considered together (OR=3; 
corrected p=0.0003) [31]. An Italian study by Arduino et al. recruited a population of 
30 women with breast cancer or multiple myeloma who had developed zoledronate-
induced ONJ cases, 30 drug, gender, disease and ethnicity-matched controls without 
ONJ, as well as 125 healthy controls [24]. Candidate gene of this study was vascular 
endothelial growth factor (VEGF), which had been previously reported to be 
associated with avascular osteonecrosis of the femoral head [54-55]. No statistically 
significant association was found for any of the three studies SNPs, -634 G>C, +936 
C>T, and -2578 C>A (p>0.05). However, the haplotype determined by rs2010963 
and rs699947 was found to be significantly associated with ONJ (corrected p=0.02). 
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Another Italian study by La Ferla et al. studied 30 zoledronate-induced ONJ cases 
and 53 zoledronate-exposed controls with multiple myeloma, breast and prostate 
cancer [29]. Participants were tested for three candidate polymorphisms including 
one aromatase and two oestrogen receptor polymorphisms, which were selected 
because of their reported effects upon bone mineral density and remodelling. 
Results showed that rs10046 (g.132810C>T), a polymorphism in gene CYP19A1, 
was more prevalent amongst ONJ cases (OR= 2.83; p=0.04). Marini et al. recruited 
64 Italian patients with multiple myeloma, breast and prostate cancer who had 
received zoledronate, 34 of whom developed ONJ [26]. They studied polymorphism 
rs2297480 in gene FDPS (farnesyl pyrophosphate synthase, a key enzyme of the 
mevalonate pathway of osteoclasts), which was found to be significantly associated 
with ONJ (p=0.03), although not genome-wide significant. This study represents the 
first attempt to investigate a candidate gene directly involved in BPs mechanism of 
action. Katz et al. recruited multiple myeloma patients only, including 12 ONJ cases 
and 66 controls, who were managed with zoledronate and/or pamidronate [23]. In 
addition to gene CYP2C8, six other candidate genes were studied based on their 
potential roles in osteoclast genesis and differentiation, bone resorption and bone 
mineral density. The results showed that, per se, all candidate genes had no effects 
on ONJ, although a combined genotype of COL1A1, RANK, MMP2, OPG and OPN 
was significantly associated with ONJ development (OR=1.2; 95% CI, 1.8 to 69.9; 
p=0.0097). 
Di Martino et al. studied 1,936 SNPs relevant to 225 genes associated with drug 
metabolism, disposition and transport in nine multiple myeloma zoledronate-treated 
patients with ONJ and 10 matched controls [25]. The authors claim that using a 
platform that interrogates only highly selective SNPs has the advantage of avoiding 
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an extremely high number of comparisons, and therefore the need for statistical 
corrections and large patient cohorts. As a consequence, the study adopted an 
uncorrected significance level of p<0.05 and reported that variants in four genes, 
PPARG, ABP1, CHST11 and CROT, were statistically significant. However, since 
nearly 2,000 SNPs were screened, Bonferroni correction was required and the 
significance threshold should be approximately 2.5E-5 instead, i.e. 0.05 divided by 
1,936 [56]. This would mean that, in fact, no SNPs reached the corrected 
significance threshold. Nonetheless, on the basis of uncorrected results, patients 
with rs1152003, top SNP in PPARG, had over 30 times higher odds of developing 
ONJ (OR=31.5; 95% CI, 2.35 to 422.32; p=0.0055). Of note, PPARG has also been 
associated with bone remodelling, bone mass density, as well as angiogenesis [25]. 
In summary, due to small sample sizes and other methodological limitations, there 
remains little robust evidence that ONJ development is associated with any of the 
candidate SNPs or genes considered in available studies.  
 
Conclusion 
There remain a number of available pharmacogenetic studies on ONJ, which are 
characterised by relatively small sample sizes and mainly represent candidate gene 
analyses. Although GWAS are considered more powerful than candidate gene 
studies due to wider genome coverage and the advantage of being hypothesis-free, 
there are currently only two GWAS on ONJ phenotype, which only investigated a 
modest number of cases and have not been appropriately replicated. Overall, no 
genome-wide significant variant has been robustly associated with the susceptibility 
to ONJ. In addition to the methodological limitations mentioned above, this may 
suggests that, if there is any genetic predisposition at all, it may be due to common 
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variants with moderate effect size, or rare variants. In the search for genome-wide 
significant SNPs for ONJ, international multicentre collaborative networks are 
required in order to study larger and better phenotyped cohorts.  
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Table 1. Summary of GWAS 
Year Population 
Underlying 
disease 
BPs type 
Case 
n 
Control 
n 
Genotyping SNP Gene Chr p-value OR [95% CI] Ref 
2008 Spanish 
Multiple 
myeloma 
Majority on 
Pamidronate 
 
Zoledronate 
22 
65 BPs 
controls 
Affymetrix 
GeneChip 
Mapping 
500K set 
 
500,568 
SNPs 
screened 
rs1934951 CYP2C8 10 1.07E-06 
12.75 [3.7-
43.5] 
[21] 
rs1934980 CYP2C8 10 4.23E-06 
13.88 [4.0-
46.7] 
rs1341162 CYP2C8 10 6.22E-06 
13.27 [3.5-
49.9] 
rs17110453 CYP2C8 10 2.15E-05 10.2 [3.2-32.1] 
2012 
North-
western, 
southern, 
eastern 
European 
descent 
Osteoporosis 
 
Breast 
cancer 
Majority on 
Zoledronate 
30 
17 BPs 
controls 
 
1,726 
population 
controls 
Illumina 
Human 
Omni 
Express 
12v1.0 chip 
 
731, 442 
SNPs 
analysed 
rs17024608 RBMS3 3 7.47E-08 5.8 [3.0-11.0] 
[28] 
rs5768434 FAM19A5 22 1.17E-07 12.6 [4.9-32.2] 
rs11064477 PHB2 12 5.16E-07 21.7 [6.5-71.9] 
12–7016684 C1S 12 5.85E-07 21.1 [6.4-69.8] 
8–58133986 IMPAD1 8 3.10E-06 7.3 [3.1-16.9] 
rs1886629 KCNT2 1 5.53E-06 3.6 [2.1-6.5] 
rs7588295 CSRNP3 2 6.24E-06 8.6 [3.3-22.17] 
rs4431170 MARCH1 4 7.28E-06 5.1 [2.5-10.6] 
rs7740004 C6orf170 6 7.87E-06 5.9 [2.7-13.0] 
rs11189381 SFRP5 10 8.17E-06 6.8 [2.9-15.8] 
rs12903202 ALDH1A2 15 9.15E-06 4.0 [2.1-7.4] 
rs17751934 MEX3C 18 9.16E-06 5.0 [2.4-10.1] 
11–
23990403 
LUZP2 11 9.94E-06 12.7 [4.0-36.8] 
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Table 2. Summary of candidate gene replication studies on CYP2C8 
Year Population 
Underlying 
disease 
BPs type 
Case 
n 
Control 
n 
Genotyping SNP Gene Chr 
p-
value 
OR [95% CI] Ref 
2010 
80% 
Caucasian 
10% 
African 
American 
Prostate 
cancer 
Zoledronate 
 
Combination 
of BPs 
17 
83 BPs 
controls 
Big Dye 
Terminator 
Cycle 
Sequencing 
Ready Reaction 
kit V3.1 
rs1934951 CYP2C8 10 >0.47 0.63 [0.17-2.42] [22] 
2011 
68% White 
24% 
African 
American 
Multiple 
myeloma 
Zoledronate 
and/or 
Pamidronate 
12 
66 BPs 
controls 
Taqman® 
Pyrosequencing 
rs1934951 CYP2C8 10 0.63 0.68 [0.14-3.22] 
[23] 
rs1934980 CYP2C8 10 0.66 0.70 [0.15-3.36] 
2011 Caucasian 
Multiple 
myeloma 
Zoledronate 42 
37 BPs 
controls 
 
45 
population 
controls 
Taqman® rs1934951 CYP2C8 10 0.13 / [27] 
2012 Hungarian 
Breast 
cancer 
 
Osteoporosis 
 
Multiple 
myeloma 
 
Prostate 
cancer 
Zoledronate 
 
Ibandronate 
 
Pamidronate 
46 
224 
population 
controls 
Taqman® rs1934951 CYP2C8 10 >0.05 / [30] 
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Table 3. Summary of discovery candidate gene studies 
Year 
Populatio
n 
Underlying 
disease 
BPs type 
Case 
n 
Control 
n 
Genotyping SNP Gene Chr p-value OR [95% CI] Ref 
2011 
68% White 
24% 
African 
American 
MM 
ZOL 
and/or PM 
12 
66 BPs 
controls 
Taqman® 
 
Pyrosequencin
g 
rs1800012 COL1A1 17 0.55 1.69 [0.30-9.70] 
[23] 
rs12458117 RANK 18 0.38 2.14 [0.39-11.71] 
rs243865 MMP2 16 0.11 3.49 [0.75-16.18] 
rs2073618 OPG 8 0.38 2.16 [0.38-12.23] 
rs3102735 OPG 8 0.75 0.79 [0.19-3.34] 
rs11730582 OPN 4 0.21 2.97 [0.53-16.55] 
rs28357094 OPN 4 0.41 0.51 [0.10-2.59] 
rs1800629 TNF 6 0.67 0.68 [0.12-3.95] 
2011 Italian BC, MM ZOL 30 
30 BPs 
controls; 
125 
population 
controls 
Taqman® 
rs3025039 
VEGF 6 
0.40 0.57 [0.21-1.54] 
[24] rs699947 0.78 0.99 [0.31-3.18] 
rs2010963 0.86 0.96 [0.37-2.53] 
2011 N/A MM ZOL 9 
10 BPs 
controls 
Affymetrix 
DMETTM plus 
platform 
 
1,936 SNPs 
analysed 
rs1152003 PPARG 3 0.0055 
/ [25] 
rs10893 
ABP1 7 
0.023 
0.023 
0.023 
rs4725373 
rs1049793 
rs2463437 
CHST11 12 
0.0198 
0.0198 
0.0198 
rs903247 
rs2468110 
rs2097937 CROT 7 0.0198 
2011 Caucasian 
BC, MM,   
PC 
ZOL 34 
34 BPs 
controls 
GoTaq® rs2297480 FDPS 1 0.03 / [26] 
2012 Caucasian 
BC, MM,   
PC 
ZOL 30 
53 BPs 
controls 
Taqman® 
rs2234693 ESR1 6 >0.05 / 
[29] rs9340799 ESR1 6 >0.05 / 
rs10046 CYP19A1 15 0.0439 2.83 
2013 White 
BC, MM,   
PC 
ZOL or PM 
or  
Combination 
of BP 
94 
110 BPs 
controls 
LABType 
single strand 
oligonucleotide 
typing kit 
DRB1*01 
MHC 6 
0.049 2.0 [0.99-4.1] 
[31] 
DRB1*15 0.014 2.3 [1.2-4.4] 
DQB1*05:01 0.050 2.0 [0.99-4.0] 
DQB1*06:02 0.014 2.3 [1.2-4.6] 
 
BC: Breast cancer; MM: Multiple myeloma; PC: Prostate cancer; ZOL: Zoledronate; PM: Pamidronate
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